Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Inclusion Criteria
- PRE-REGISTRATION INCLUSION CRITERIA:
- United States (US) and Canadian sites: * This review is mandatory prior to registration to confirm eligibility; patients must be willing to submit tissue samples for mandatory central pathology review submission; it should be initiated as soon after surgery as possible
- Tissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review * Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility, the 1p/19q analysis results will be accepted from the local site, as determined by either a locally available or reference laboratory (for US, must be Clinical Laboratory Improvement Act [CLIA] certified); acceptable methods for determination of 1p/19q loss include fluorescent in-situ hybridization (FISH), by genomic sequencing or methylomic analyses; US and Canadian sites must send a copy of the official report to the pathology coordinator and quality assurance specialist (QAS) * Tumor must also show evidence of IDH mutation by immunohistochemistry or genomic analyses; this should be performed at the local site (US: performed in a CLIA certified laboratory); the site must send a copy of the official report to the pathology coordinator and QAS
- REGISTRATION INCLUSION CRITERIA:
- Newly diagnosed and =< 3 months from surgical diagnosis; patients are also eligible if they have had a prior surgical procedure > 3 months earlier for low grade glioma, as long as the patient has not received prior radiation or prior chemotherapy
- Histological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p/19q loss and the presence of an either IDH1 or IDH2, both as established by a local or referenced laboratory qualified for the study * Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19q
- Patients with codeleted low grade gliomas must also be considered “high risk” by exhibiting one or more of the following characteristics: * Age >= 40 and any surgical therapy * Age < 40 with prior and subtotal resection or biopsy (i.e., anything less than gross total resection) * Documented growth following prior surgery (NOTE: patients with prior surgery cannot have received prior radiation, chemotherapy or targeted therapy) * Intractable seizures
- Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery
- Absolute neutrophil count (ANC) >= 1,500/mm^3 (obtained =< 21 days prior to registration)
- Platelet (PLTs) count >= 100,000/mm^3 (obtained =< 21 days prior to registration)
- Hemoglobin (Hgb) > 9.0 g/dL (obtained =< 21 days prior to registration)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 21 days prior to registration)
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN (obtained =< 21 days prior to registration)
- Creatinine =< 1.5 x ULN obtained =< 21 days prior to registration
- Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Willingness and ability to personally complete neurocognitive testing (without assistance) and willingness to complete the QOL testing, (either personally or with assistance)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2
- Written informed consent
- Willingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose
- Willingness to allow the provision of tissue samples for correlative research, as long as adequate tissues are available; patients will not be excluded from participation in the study, if they are willing to allow provision of tissues for the correlative research, but there are insufficient quantities of tissue for the correlative analyses (e.g., a patient otherwise eligible and willing who had biopsy only) Willingness to allow the provision of blood samples for correlative research; patients are not excluded from participation in the study, if they are willing to provide the mandatory biospecimens for translational/correlative research, but for logistical reasons the specimens(s) were not obtainable or if the volume collected was insufficient
Exclusion Criteria
- The following categories are ineligible: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception or contraceptive method during this study and 6 months following the completion of chemotherapy treatments
- History of prior radiation therapy or chemotherapy for glioma; note: patients who have a history of prior low grade glioma (with or without a distant history of prior surgery for that glioma), but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the study
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Concomitant serious immunocompromised status (other than that related to concomitant steroids) that would compromise the safety of the patient on the study
- Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
- Other active malignancy within 5 years of registration; exceptions: non-melanotic skin cancer or carcinoma-in-situ of the cervix; note: if there is a history of prior malignancy, the patient is not eligible if they are receiving other specific treatment (with the exclusion of hormonal therapy or Her-2 inhibitors) for their cancer or if they have received prior total body irradiation which included the brain
- History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis
Alabama
Birmingham
Mobile
Alaska
Anchorage
Arizona
Phoenix
Scottsdale
California
Anaheim
Auburn
Burlingame
Cameron Park
Clovis
La Jolla
Los Angeles
Modesto
Oakland
Ontario
Orange
Roseville
Sacramento
Santa Clara
South San Francisco
Vacaville
Vallejo
Colorado
Aurora
Colorado Springs
Denver
Lakewood
Littleton
Longmont
Loveland
Parker
Pueblo
Connecticut
New Haven
Trumbull
District of Columbia
Washington
Florida
Boca Raton
Gainesville
Jacksonville
Orlando
Georgia
Atlanta
Idaho
Caldwell
Post Falls
Illinois
Bloomington
Canton
Carthage
Centralia
Chicago
Decatur
Effingham
Eureka
Galesburg
Kewanee
La Grange
Macomb
Maywood
O'Fallon
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
Springfield
Indiana
Fort Wayne
Mishawaka
South Bend
Iowa
Ames
Clive
Creston
Des Moines
West Des Moines
Kansas
Kansas City
Overland Park
Westwood
Kentucky
Lexington
Louisville
Louisiana
Marrero
Maine
Portland
Scarborough
South Portland
Maryland
Baltimore
Bethesda
Rockville
Massachusetts
Boston
Michigan
Adrian
Ann Arbor
Detroit
Grand Rapids
Kalamazoo
Royal Oak
Traverse City
Troy
Minnesota
Burnsville
Coon Rapids
Duluth
Edina
Fridley
Maplewood
Minneapolis
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Waconia
Willmar
Woodbury
Missouri
Cape Girardeau
Columbia
Kansas City
Lee's Summit
North Kansas City
Saint Louis
Montana
Billings
Great Falls
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Scottsbluff
Nevada
Las Vegas
Reno
New Hampshire
Lebanon
New Jersey
New Brunswick
Summit
New Mexico
Albuquerque
New York
Brooklyn
New York
Rochester
Syracuse
North Carolina
Winston-Salem
North Dakota
Grand Forks
Ohio
Cleveland
Columbus
Mayfield Heights
Sylvania
Westerville
Wooster
Oklahoma
Oklahoma City
Tulsa
Oregon
Clackamas
Gresham
Portland
Pennsylvania
Abington
Allentown
Bethlehem
Danville
Philadelphia
Pittsburgh
West Reading
Wilkes-Barre
South Carolina
Boiling Springs
Charleston
Greenville
Greer
Seneca
Spartanburg
South Dakota
Rapid City
Tennessee
Nashville
Texas
Dallas
Galveston
League City
Utah
Cedar City
Murray
Provo
Saint George
Salt Lake City
Virginia
Richmond
South Hill
Washington
Bellingham
Kennewick
Mount Vernon
Seattle
Vancouver
West Virginia
Morgantown
Wisconsin
Ashland
La Crosse
Milwaukee
Oconomowoc
Waukesha
Alberta
Calgary
Edmonton
British Columbia
Vancouver
Manitoba
Winnipeg
Ontario
London
Ottawa
Toronto
Quebec
Montreal
Saskatchewan
Regina
Austria
Vienna
Belgium
Antwerpen
France
Lyon
Nice
Villejuif
Netherlands
Amsterdam
Groningen
Maastricht
Rotterdam
PRIMARY OBJECTIVES:
I. To determine whether patients who receive radiotherapy with concomitant temozolomide followed by adjuvant temozolomide (radiation therapy [RT] + temozolomide [TMZ] → TMZ) (ARM B) have a marginally better progression free survival (PFS) as compared with patients who receive radiotherapy followed by adjuvant procarbazine hydrochloride, lomustine, vincristine sulfate (PCV) chemotherapy (RT → PCV) (ARM A).
SECONDARY OBJECTIVES:
I. To determine whether patients who receive temozolomide RT + TMZ → TMZ have a longer time to progression (clinical or radiographic progression) as compared with patients who receive radiotherapy followed by adjuvant PCV chemotherapy (RT → PCV).
II. To determine whether there is a difference in survival based on (1;19)(q10,p10) translocation status and MGMT promoter hypermethylation status.
III. To perform descriptive comparisons of additional secondary outcome endpoints, including overall survival, objective tumor response, prognostic factor analysis and quality of life, including comparisons between photon and proton radiotherapy.
IV. To determine the toxicity of the treatment in each arm and perform descriptive comparisons as well as comparisons between photon and proton radiotherapy.
V. To determine the neurocognitive and quality of life (QOL) effects in patients treated on this protocol and correlate these results with outcome endpoints as well as comparisons between photon and proton radiotherapy.
VI. To store biospecimens (plasma or serum, deoxyribonucleic acid [DNA] from tumor and peripheral blood mononuclear cells DNA, tumor tissue, and magnetic resonance imaging [MRI]/ computed tomography [CT] images) for future correlative scientific investigations which explore the scientific relationships of any known and yet-to-be developed markers to clinical outcome and imaging data.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients undergo 3-dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride orally (PO) on days 8-21, lomustine PO on day 1 and vincristine sulfate intravenously (IV) on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo IMRT as in Arm A and receive temozolomide PO once daily (QD) on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD on days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
After completion of study therapy, patients are followed up every 12 weeks for 1 year, every 4 months for 2 years, and then every 6 months thereafter.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Alliance for Clinical Trials in Oncology
Principal Investigator
Kurt A. Jaeckle
- Primary ID N0577
- Secondary IDs NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577
- Clinicaltrials.gov ID NCT00887146